Sign up
Pharma Capital

Pharmaxis reveals a quarterly shareholder update full of highlights

Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips discusses with Proactive Investors the highlights contained within the biotech company’s latest Quarterly Shareholder Update.


“The one thing which really caught everyone’s attention was Boehringer Ingelheim starting a second indication with the drug they licensed from us,” notes Phillips. That development garnered a $15 million milestone payment.


Meanwhile, two compounds from the anti-fibrotic LOXL2 program have entered the clinic for phase one testing. The quarter also saw sales of Bronchitol improve in Europe and Australia.

 

View full PXS profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.